Docetaxel resistant sub-lines were generated in the androgen-independent (PC-3, DU-145) and sensitive (22RV1) cell lines
| Inventor | Institute |
|---|---|
| William G Watson | University College Dublin |
| SKU: | 161581 |
|---|---|
| Product description: | Docetaxel resistant sub-lines were generated in the androgen-independent (PC-3, DU-145) and sensitive (22RV1) cell lines. One of the main mechanisms of resistance to Docetaxel is the over expression of P-gp which would reduce intracellular concentrations of the drug through increased efflux. Chemoresistant PC-3 cells do not over express P-gp. We demonstrated that the resistance in the PC-3 sublines was independent of P-gp over expression as there were no detectable levels and no effects of the P-gp inhibitor Elacridar on their resistance |
| Alternate name: | PC-3 Docetaxel resistant cell line |
| CRISPR: | No |
| Production details: | PC-3 resistant sub-lines were generated by initially treating with Docetaxel (Sigma) at 4 nM and 8 nM (suspended in dimethyl sulfoxide (DMSO) (Fluke)) in 75 cm2 flasks for 48 hours. After treatment, the surviving cells were re-seeded into new flasks and allowed to recover for 2-3 weeks. After 5 (at 8 nM) and 7 (at 4 nM) treatments, the dose of docetaxel was increased from 4 nM and 8 nM to 8 nM and 12 nM respectively. The cells underwent a total of 18 treatment cycles at 8 nM and 12 treatment … |
| Disease: | Cancer |
| Products or characteristics of interest: | Docetaxel resistant cell line |
| Cat. #: | 161581 |
|---|---|
| Cancer types: | Prostate cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Pancreas |
| Model: | Mutant |
| Growth properties: | Suspension |
| Cancer Types In Detail: | Prostate |
| Primary citation: | O’Neill et al. Mol Cancer. 2011 Oct 7;10:126. PMID: 21982118 |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry Ice |
| Growth medium: | RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 50 U/ml penicillin/50 ?g/ml streptomycin and 2 mM L-glutamine |
| References: |
O'Neill et al. Mol Cancer. 2011 Oct 7 10:126. PMID: 21982118 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.